PEPTIDEPEDIA
انضم
تصوير الهيكل المثالي لـ GHRP-2
P 018GHRP-2

المطابق المثالي المبني من التسلسل؛ ليست بنية تجريبية أو متوقعة.

تصوير الهيكل المثالي لـ البنية الكيميائية لـ GHRP-2 (ثنائية الأبعاد)
P 018 · 2Dالبنية الكيميائية (ثنائية الأبعاد)

تصوير ثنائي الأبعاد من PubChem SMILES

P 018تم التحقق 2026-08-06
approved diagnostic

GHRP-2

الأسماء المستعارة: Pralmorelin · KP-102 · GPA-748 · Growth Hormone Releasing Peptide-2 · KP-102D · KP-102LN

Approved in Japan (2004) as a diagnostic agent for GH deficiency under the name Pralmorelin (Kaken Pharmaceutical); PMDA-approved pediatric exposure is 2 mcg/kg by slow IV injection (ages 4–17, cap 100 mcg), and the adult exposure is 100 mcg by slow IV injection — a single-administration diagnostic test, not a therapeutic regimen; therapeutic development for short stature discontinued after Phase II intranasal trial failure; never approved by FDA or EMA.

محور النموفي المزيج: CJC-1295/GHRP-2

يتم الاحتفاظ بمحتوى الأدلة باللغة الإنجليزية.

تصوير الهيكل المثالي لـ GHRP-2

المطابق المثالي المبني من التسلسل؛ ليست بنية تجريبية أو متوقعة.

لمحة سريعة

ENTRY TYPE
approved diagnostic
IDENTITY
Sequence verified

No structure asset recorded

TOP EVIDENCE
Grade A — GHD diagnosis (adults and children)
MAJOR STATUS
Jurisdiction-specific — see status table
SPORT
Prohibited — as of 2026-08-06
VERIFIED
2026-08-06

Bottom line

GHRP-2 (pralmorelin) is a synthetic hexapeptide ghrelin-receptor agonist. It received regulatory approval in Japan in 2004 as a diagnostic agent for growth hormone deficiency. A separate 48-week, randomized intranasal-treatment trial in 126 children found no significant improvement in growth despite increasing GH secretion; that treatment study was not the basis for the diagnostic evidence summarized below. Human pharmacology studies report that GHRP-2 can also affect ACTH, cortisol, and prolactin.

Identity and composition

FieldVerified information
Preferred nameGHRP-2 (Pralmorelin)
Key aliasesKP-102, GPA-748, Growth Hormone Releasing Peptide-2, pralmorelin
Molecular/sequence identityHexapeptide: D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH2
Modifications/formD-amino acids at positions 1, 2, and 5 confer metabolic stability; D-2-naphthylalanine (D-2-Nal) at position 2 enhances binding affinity
Stable identifiers: 6918245; CAS: 158861-67-7; MW ~818 Da
Identity caveatsNot to be confused with GHRP-6 (His-D-Trp-Ala-Trp-D-Phe-Lys-NH2, ~873 Da). Assay-specific potency comparisons should not be converted into human-dose equivalence.

Development and approval status

JurisdictionStatus and indicationProduct/sourceAs of
Japan (PMDA)Approved 2004 for diagnostic testing of GH deficiencyPralmorelin (Kaken Pharmaceutical)2026-08-06
US (FDA)No approved indication; development discontinued—2026-08-06
EU (EMA)No marketing authorization—2026-08-06
Status is multi-axis
GHRP-2 authorization and sport-status profileFour medicine-authorization axes reproduce only documented status rows; sport status is shown separately.UNITED STATESNo approved indication;development discontinuedSOURCE / AS OFROW 2 / 2026-08-06EU/EEANo marketing authorizationSOURCE / AS OFROW 3 / 2026-08-06UNITED KINGDOMSOURCE ROW OMITTEDSEE AUDIT REASONSOURCE / AS OFNOT PRESENT / NOT RECORDEDOTHER DOCUMENTEDApproved 2004 for diagnostictesting of GH deficiencySOURCE / AS OFROW 1 / 2026-08-06SPORT STATUS — SEPARATE FROM MEDICINE AUTHORIZATIONPralmorelin is a prescription diagnostic in Japan. The 2026 WADA Prohibited List explicitlynames GHRP-2 (pralmorelin) among GH-releasing peptides in section S2.2.4; it is prohibited
Authorization belongs to the named product, use, place, and date; sport status is independent.
بديل نصي
UNITED STATES
US (FDA): No approved indication; development discontinued
EU/EEA
EU (EMA): No marketing authorization
UNITED KINGDOM
No UNITED KINGDOM row is present in the source status table
OTHER DOCUMENTED
Japan (PMDA): Approved 2004 for diagnostic testing of GH deficiency

Sport status: Pralmorelin is a prescription diagnostic in Japan. The 2026 WADA Prohibited List explicitly names GHRP-2 (pralmorelin) among GH-releasing peptides in section S2.2.4; it is prohibited at all times. It has been detected in seized nutritional supplements (Thomas et al., Drug Test Anal 2010; PMID: 20878896).

Mechanism and pharmacology

GHRP-2 is an agonist at the ghrelin receptor (GHS-R1a) on pituitary somatotroph cells and can provoke an acute GH response. Human pharmacology studies also report effects on ACTH, cortisol, and prolactin. Route-specific observations from small studies should not be generalized to unapproved therapeutic use.

Evidence by claim

Claim/indicationStageGradeBest human evidenceMain resultImportant limitations
GHD diagnosis (adults and children)Approved (Japan)APMDA product record and 2014 re-examination report; 503 postmarketing cases from 19 institutions, with 502 in the effectiveness analysisAgainst clinician diagnosis based on at least two other GH-stimulation agents, the 9 ng/mL criterion for severe GHD had sensitivity 0.853 and specificity 0.885; ROC AUC 0.939Japan-specific product and indication; postmarketing comparison was retrospective and does not establish therapeutic use
Short stature treatmentPhase II (discontinued) [1]XTanaka et al., 2014; intranasal GHRP-2 in short GHD childrenIncreased GH secretion but no clinically significant growth promotionIntranasal route; therapeutic program discontinued
GH release (acute pharmacology)Phase I [1]CPihoker et al., J Clin Endocrinol Metab 1998; ten prepubertal short childrenAcute GH response and PK/PD parameters characterized after one exposurePharmacology endpoints only; small, selected pediatric population
Food intake/metabolismHuman studyCLaferrère et al., J Clin Endocrinol Metab 2005; seven lean healthy menA 270-minute infusion increased buffet-meal energy intake by 35.9% versus salineAcute crossover experiment; small N
درجات الأدلة
  • Aالدرجة A: مثبت لاستخدام محدد مصرح به
  • Bالدرجة B: أدلة بشرية معتدلة
  • Cالدرجة C: أدلة بشرية أولية
  • Dالدرجة D: ما قبل السريرية فقط
  • Eالدرجة E: ادعاء قصصي/تسويقي
  • Xالدرجة X: الأدلة تتعارض مع الادعاء أو لا تدعمه
تعرف على المزيد حول تصنيف الأدلة
Claim-evidence profile
GHRP-2 claim-evidence profileA: 1 claim; B: 0 claims; C: 2 claims; D: 0 claims; E: 0 claims; X: 1 claimCONTRADICTORY / NON-SUPPORTIVEA — Established for a specific labeled useGrade A: Established for a specific labeled use — current approval plus adequate controlled trials and post-market context.1 claimGHD diagnosis (adults and children)B — Moderate human evidenceGrade B: Moderate human evidence — multiple controlled studies or a strong pivotal study, but no current approval for the claim.0 claimsC — Preliminary human evidenceGrade C: Preliminary human evidence — small, uncontrolled, surrogate-endpoint, or early-phase studies.2 claimsGH release (acute pharmacology)Food intake/metabolismD — Preclinical onlyGrade D: Preclinical only — in vitro or animal evidence with no adequate human efficacy evidence.0 claimsE — Anecdotal/marketing claimGrade E: Anecdotal/marketing claim — testimonials, extrapolation, or vendor claims without adequate scientific support.0 claimsX — Evidence contradicts or does not support the claimGrade X: Evidence contradicts or does not support the claim — adequate negative evidence, failed program, or claim inconsistent with the studied material.1 claimShort stature treatment
This counts the page's claim rows; it does not average them into a score.
بديل نصي

Text alternative for the claim-evidence diagram. Each grade is defined below:

A — Established for a specific labeled use
1 claim: GHD diagnosis (adults and children)
B — Moderate human evidence
0 claims
C — Preliminary human evidence
2 claims: GH release (acute pharmacology); Food intake/metabolism
D — Preclinical only
0 claims
E — Anecdotal/marketing claim
0 claims
X — Evidence contradicts or does not support the claim
1 claim: Short stature treatment
United StatesNo approved indication; development discontinued
EU/EEANo marketing authorization
OtherApproved 2004 for diagnostic testing of GH deficiency

Key studies

StudyDesign/populationExposure studiedEndpoints and resultLimitations
PMDA re-examination report (2014)Official regulatory reassessment; 503 postmarketing cases from 19 Japanese institutions, 502 in effectiveness analysisJapan-labeled single diagnostic administrationAt the 9 ng/mL severe-GHD criterion, sensitivity was 0.853, specificity 0.885, and ROC AUC 0.939 versus clinician diagnosis using at least two other stimulation agentsRetrospective postmarketing comparison; not a randomized trial or therapeutic study
Drugs R&D drug profile (2004); PMID: 15230633Secondary, unsigned development-profile article summarizing pralmorelin's pharmacology and then-current development status [1]Not a primary trial reportDescribed the diagnostic rationale and reported a 15 mcg/L peak-GH threshold from the development recordSecondary source; published before Japanese approval and should not be cited as the primary multicenter diagnostic trial
Pihoker et al., J Clin Endocrinol Metab 1998; PMID: 9543135Phase I PK/PD; ten prepubertal short children (nine boys and one girl; mean age 7.7 years) [1]One 1 mcg/kg exposure over 1 minuteTerminal 0.55 hours; GH reached maximum concentration at 0.42 hoursPharmacology study only; small, selected pediatric population
Tanaka et al., Clin Pediatr Endocrinol 2014; PMID: 25148835Phase II; short children with GHD [1]Intranasal GHRP-2 sprayIncreased GH but no significant height velocity improvementTherapeutic program discontinued
Laferrère et al., J Clin Endocrinol Metab 2005; PMID: 15699539Randomized within-subject comparison; seven lean healthy men [1] infusion at 1 mcg/kg/hour for 270 minutesFood intake increased 35.9% versus saline; serum GH also increasedAcute setting only; small N; not a therapeutic dose-finding study

Dose and administration evidence

Approved labeled regimen

The label summary below is product-, indication-, and jurisdiction-specific; consult the full current label and a licensed clinician/pharmacist.

Japan-approved diagnostic exposure (PMDA): 2 mcg/kg by slow injection for ages 4–17 years, capped at 100 mcg; 100 mcg by slow IV injection for adults, administered fasting. A peak GH cutoff of 16 ng/mL is used for children; 9 ng/mL for adults. This is a single-administration diagnostic test for GH deficiency — not a therapeutic regimen and not guidance for self-administration.

Studied regimens (not recommendations)

No established or recommended human dose. This sentence concerns therapeutic and other unapproved use; it does not erase the separate Japan-specific, single-administration diagnostic label above. Published nontherapeutic pharmacology studies used protocol-specific exposures under research oversight; they do not establish a therapeutic regimen.

What is not established

  • Effective therapeutic dose for any non-diagnostic indication

  • Safety or efficacy of chronic daily administration

  • Dose finding for body composition or performance claims

Safety

Established label risks

The PMDA re-examination report recorded no adverse drug reactions among 503 postmarketing cases, while the preapproval Japanese trials recorded adverse drug reactions in 86 of 227 participants (37.9%), most commonly borborygmi, feeling hot, sweating, and increased white-blood-cell count. These product-specific diagnostic data do not establish chronic-use safety.

Human-study signals

At higher or repeated doses, GHRP-2 can elevate cortisol and prolactin. Mild injection-site reactions, transient flushing, and increased appetite have been reported.

Unknowns and product-quality risks

Long-term safety (beyond single/diagnostic administration) is not established. No Phase III therapeutic safety data exist. Research-grade material is unregulated.

Interactions and special populations

No formal drug-interaction studies. Diagnostic use should avoid concomitant GH-suppressing medications.

Regulatory, compounding, and sport notes

Pralmorelin is a prescription diagnostic in Japan. The 2026 Prohibited List explicitly names GHRP-2 (pralmorelin) among GH-releasing peptides in section S2.2.4; it is prohibited at all times. It has been detected in seized nutritional supplements (Thomas et al., Drug Test Anal 2010; PMID: 20878896).

Evidence gaps

  • No Phase III therapeutic efficacy trial

  • No long-term safety data beyond diagnostic single-dose use

  • No adequate human body-composition data

  • No studies in women for most endpoints

  • No approved therapeutic indication outside Japan

Search notes

  • Databases and registries: PubMed, ClinicalTrials.gov, PMDA (Japan), FDA Drugs@FDA

  • Search terms: "GHRP-2", "pralmorelin", "KP-102", "growth hormone releasing peptide 2"

  • Last searched: 2026-08-06

  • Inclusion emphasis: Human studies; regulatory documents; primary peer-reviewed data

Sources

  1. Drugs R&D. Pralmorelin: GHRP 2, GPA 748, growth hormone-releasing peptide 2, KP-102 D, KP-102 LN. 2004;5(4):236-239. PMID: 15230633. PubMed classifies this unsigned article as a review; it is a development profile, not the primary multicenter diagnostic trial report. https://pubmed.ncbi.nlm.nih.gov/15230633/

  2. Pihoker C et al. Pharmacokinetics and pharmacodynamics of GHRP-2: a phase I study in children. J Clin Endocrinol Metab. 1998;83(4):1168-1172. https://pubmed.ncbi.nlm.nih.gov/9543135/

  3. Tanaka T et al. Intranasal GHRP-2 in short children with GH deficiency. Clin Pediatr Endocrinol. 2014;23(4). https://pubmed.ncbi.nlm.nih.gov/25148835/

  4. Laferrère B et al. Growth hormone-releasing peptide-2 (GHRP-2), like ghrelin, increases food intake in healthy men. J Clin Endocrinol Metab. 2005;90(2):611-614. PMID 15699539. https://pubmed.ncbi.nlm.nih.gov/15699539/

  5. Thomas A et al. Identification of GHRP-2 in a nutritional supplement. Drug Test Anal. 2010;2(3):144-148. https://pubmed.ncbi.nlm.nih.gov/20878896/

  6. WADA. 2026 Prohibited List, section S2.2.4. https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf

  7. PubChem CID 6918245. https://pubchem.ncbi.nlm.nih.gov/compound/6918245

  8. Pharmaceuticals and Medical Devices Agency. GHRP Kaken 100 (pralmorelin hydrochloride), current product information. https://www.pmda.go.jp/PmdaSearch/rdDetail/iyaku/7223407D2023_1?user=1

  9. Pharmaceuticals and Medical Devices Agency. Re-examination report for GHRP Kaken 100 (approved indication and labeled diagnostic administration). https://www.pmda.go.jp/drugs_reexam/2014/P201400051/20002200_21600AMZ00573_A100_1.pdf

أصوات الخبراء

ماذا يقول الخبراء

التعليقات آراء شخصية وليست جزءًا من مراجعة الأدلة؛ والإدراج لا يعني المصادقة.

لم يتم العثور على تعليقات خبراء موثقة لهذا المركب في المصادر التي يقبلها هذا الأطلس — الأدبيات المحكمة، واتصالات الجامعات والمستشفيات والجمعيات الطبية، والجهات التنظيمية، والصحافة العلمية الموقعة.

غياب التعليقات ليس دلياً على المركب بأي من الاتجاهين.

ادعاءات البائعين والعيادات ووسائل التواصل الاجتماعي مستبعدة بموجب السياسة ولا تُحتسب كتعليقات.

فيديو

أسئلة

What is GHRP-2 and what is its relationship to pralmorelin?

GHRP-2 (pralmorelin) is a synthetic hexapeptide ghrelin-receptor agonist. It received regulatory approval in Japan in 2004 as a diagnostic agent for GH deficiency under the name Pralmorelin (Kaken Pharmaceutical). It is not to be confused with GHRP-6, which has a different sequence and molecular weight.

Is GHRP-2 approved by the FDA or EMA?

No. The monograph documents approval in Japan as a single-administration diagnostic test for GH deficiency, no FDA-approved indication in the US, and no EMA marketing authorization in the EU. Status in other jurisdictions is not established here. Therapeutic development for short stature was discontinued after a Phase II trial of a nasal formulation found no clinically significant growth promotion.

What human evidence supports GHRP-2 for therapeutic use?

A phase 2 trial in children with growth hormone deficiency found increased GH secretion but no clinically significant growth promotion, and the therapeutic program was discontinued. A small acute study in seven men reported increased food intake versus saline. These nontherapeutic pharmacology findings do not establish a therapeutic regimen. No phase 3 therapeutic efficacy trial exists. No established or recommended human dose.

What are the main safety signals for GHRP-2?

Preapproval Japanese trials recorded adverse drug reactions in 86 of 227 participants (37.9%), most commonly borborygmi, feeling hot, sweating, and increased white-blood-cell count. Human pharmacology studies also report effects on cortisol and prolactin. Long-term safety beyond single diagnostic use is not established.

Is GHRP-2 prohibited by WADA?

Yes. The 2026 WADA Prohibited List explicitly names GHRP-2 (pralmorelin) among GH-releasing peptides in section S2.2.4; it is prohibited at all times. It has been detected in seized nutritional supplements.

What evidence supports the Japan-approved diagnostic use of GHRP-2?

A 2014 PMDA re-examination included 503 postmarketing cases, with 502 in the effectiveness analysis. Against clinician diagnosis based on at least two other GH-stimulation agents, the reported severe-GHD criterion had sensitivity 0.853, specificity 0.885, and ROC AUC 0.939. The comparison was retrospective and does not establish therapeutic use.

ذو صلة

الفئة: محور النموالسابق: Ipamorelinالتالي: GHRP-6مزيج: CJC-1295/GHRP-2ملخصات اللوائح ذات الصلةأدلة الجرعات
تحديثات البحوث

انضم إلى الأطلس. واحصل على تحديثات الأدلة.

احصل على ملاحظات موجزة عندما تتغير أدلة الببتيد أو الحالة أو سجلات المصدر.